View Document Preview and Link Document Date: 2014-02-06 00:38:27 Open Document File Size: 87,51 KB Share Result on Facebook
City LEXINGTON / / Company Synta Pharmaceuticals Corp. / ArQule Inc. / Edwards Wildman Palmer LLP / Galenea Corp. / VaxDesign Corporation / Avaxia Biologics Inc. / / Currency USD / / Event Employment Change / / Facility Bowdoin College / University of Massachusetts / / IndustryTerm Potential applications / pharmaceutical industry / biotechnology industry / corporate law / law / privately-held biotechnology company developing oral antibody drugs / / MedicalCondition IBD / celiac disease / inflammatory bowel disease / GI acute radiation syndrome / disease / oral mucositis / diabetes / AVX Oral Antibodies make disease / obesity / / MedicalTreatment antibody therapy / radiation / / Organization University of Massachusetts / Bowdoin College / UCLA School of Law / / Person Barbara S. Fox / Michael D. Rivard / / Position Attorney / Counsel / CEO / VP Corporate Development LEXINGTON / Vice President / Corporate Development / / ProvinceOrState Massachusetts / / Technology radiation / antibodies / biotechnology / AVX Oral Antibody technology / / SocialTag 
Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development LEXINGTON, Mass. – June 12, 2012 – Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs